Skip to search formSkip to main contentSkip to account menu

ABT-806

Known as: anti-EGFR MoAb ABT-806, anti-EGFR mAb ABT-806 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Antibodies, Monoclonal, Humanizedmonoclonal antibody 806

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
ABT-806 derived antibody drug conjugates (ADCs) inhibit growth of malignant mesothelioma in-vivo.
e14677 Background: Malignant mesothelioma (MM) is an aggressive malignancy of the pleura with limited therapeutic options, and is… 
2017
2017
A Phase 1 and Biodistribution Study of Abt-806I, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-Egfr Antibody Abt-806
2016
2016
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).
2542Background: Recurrent GBM (rGBM) has dismal prognosis. Almost 50% GBM tumors harbor amplified (amp) EGFR. ABT-414 is a tumor… 
2015
2015
Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR…
Background and ObjectivesABT-806 is a veneered ‘humanized’ recombinant IgG1κ antibody that is specific for a unique epitope of… 
2015
2015
ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR).
2510 Background: Aberrant EGFR expression and signaling has been identified as a hallmark of cancer growth and survival. ABT-414… 
2015
2015
ATNT-01ABT-414 MONO- OR COMBINATION THERAPY WITH TEMOZOLOMIDE (TMZ) RECHALLENGE IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM) AND AMPLIFIED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR): A PHASE I STUDY
BACKGROUND: Aberrant EGFR signaling plays a vital role in GBM oncogenesis. ABT-414 is an antibody-drug conjugate with a toxic… 
2013
2013
Abstract 870: A clinical study of ABT-806, a humanized recombinant anti-EGFR monoclonal antibody, in patients with recurrent glioblastoma multiforme.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background: Glioblastoma (GBM), the most common… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)